Bristol Myers Squibb Presents First Data From Phase 3 EXCALIBER-RRMM Trial Evaluating Iberdomide Combination in Multiple Myeloma
Bristol Myers Squibb (BMS) presented Phase 3 EXCALIBER-RRMM trial data showing iberdomide (ZENBEXUS) with daratumumab and dexamethasone achieved higher MRD-negative CR rates (41%) vs. standard therapy (21%) in relapsed/refractory multiple myeloma. The FDA granted accelerated approval for this combination in August 2026. Trial continues evaluating PFS and safety.
How this was made
The 30-second read
Why it matters
The trial's MRD-negative CR rate of 41% versus 21% for standard therapy signals a potentially differentiated product, likely influencing analyst forecasts.
Market read
Positive Phase 3 data could drive BMY stock higher and affect the broader oncology biotech sector.
What to watch
Reimbursement negotiations and competition from other myeloma agents could temper market impact.
Background
BMY recently received FDA accelerated approval for ZENBEXUS based on earlier data; this new Phase 3 data further validates the regimen.
Ticker impact
Bristol Myers Squibb presented first Phase 3 EXCALIBER-RRMM trial data showing higher MRD-negative CR rates for iberdomide combo.
potential upside of 5-10% over the next weeks
Phase 3 data with statistically significant improvement is material for a large biotech; investors may reprice future revenue expectations.
Market effects
strengthens the multiple myeloma therapeutic pipeline and may benefit peers developing CELMoD agents.
U.S. biotech sector may see modest rally on positive oncology data.
global investors tracking oncology breakthroughs will note BMY's progress.
Counterpoint
If longer-term safety concerns emerge, the initial enthusiasm could fade, limiting price gains.
Key entities
- companyBristol Myers Squibb
US-listed biotech developing iberdomide.
- drugIberdomide (ZENBEXUS)
Next‑generation CELMoD therapy for multiple myeloma.
